J
Judith S. Kaur
Researcher at Mayo Clinic
Publications - 112
Citations - 4335
Judith S. Kaur is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Cancer & Population. The author has an hindex of 29, co-authored 110 publications receiving 3839 citations.
Papers
More filters
Journal ArticleDOI
Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives.
David K. Espey,Xiao-Cheng Wu,Xiao-Cheng Wu,Judith Swan,Charles L. Wiggins,Melissa A. Jim,Elizabeth Ward,Phyllis A. Wingo,Holly L. Howe,Lynn A. G. Ries,Barry A. Miller,Ahmedin Jemal,Faruque Ahmed,Nathaniel Cobb,Judith S. Kaur,Brenda K. Edwards +15 more
TL;DR: The 2007 report features a comprehensive compilation of cancer information for American Indians and Alaska Natives (AI/AN).
Journal ArticleDOI
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
Paul E. Goss,James N. Ingle,Kathleen I. Pritchard,Nicholas J. Robert,Hyman B. Muss,Julie R. Gralow,Karen A. Gelmon,Timothy J. Whelan,Kathrin Strasser-Weippl,Sheldon Rubin,Keren Sturtz,Antonio C. Wolff,Eric P. Winer,Clifford A. Hudis,Alison Stopeck,J. Thaddeus Beck,Judith S. Kaur,Kate Whelan,Dongsheng Tu,Wendy R. Parulekar +19 more
TL;DR: The extension of treatment with an adjuvant aromatase inhibitor to 10 years resulted in significantly higher rates of disease-free survival and a lower incidence of contralateral breast cancer than those with placebo, but the rate of overall survival was not higher with the aromat enzyme inhibitor than with placebo.
Journal ArticleDOI
Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
Evanthia Galanis,Lynn C. Hartmann,William A. Cliby,Harry J. Long,Prema P. Peethambaram,Brigitte A. Barrette,Judith S. Kaur,Paul Haluska,Ileana Aderca,Paula J. Zollman,Jeff A. Sloan,Gary L. Keeney,Pamela J. Atherton,Karl C. Podratz,Sean C. Dowdy,C. Robert Stanhope,Timothy O. Wilson,Mark J. Federspiel,Kah-Whye Peng,Stephen J. Russell +19 more
TL;DR: The findings indicate that i.p. administration of MV-CEA is well tolerated and results in dose-dependent biological activity in a cohort of heavily pretreated recurrent ovarian cancer patients.
Journal ArticleDOI
Alcohol and Cancer: A Statement of the American Society of Clinical Oncology
TL;DR: ASCO joins a growing number of international organizations by establishing a platform to support effective public health strategies in this area and identifies areas of needed research regarding the relationship between alcohol use and cancer risk and outcomes.
Journal ArticleDOI
Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.
Patrick A. Burch,Gary A. Croghan,Dennis A. Gastineau,Lori A. Jones,Judith S. Kaur,Jelle Kylstra,Ronald L. Richardson,Frank H. Valone,Stanimir Vuk-Pavlović +8 more
TL;DR: This Phase 2 trial determined the efficacy of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein containing prostatic acid phosphatase (PAP) and GM‐CSF.